Shanghai Junshi Biosciences Co., Ltd. (01877)
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to tre
CS Hotline: +852 3018 4526
Trading days: 24 hours | Non-trading days: 9:00-18:00
